mm-36 and Dermatitis--Allergic-Contact

PDE4 inhibitors are expected to be anti-inflammatory agents based on their mechanism of action, but the application of this drug class is limited by a narrow therapeutic window due to adverse effects associated with gastrointestinal function. Difamilast, a novel selective phosphodiesterase 4 (PDE4) inhibitor, demonstrated significant efficacy without adverse reactions such as nausea and diarrhea in patients with atopic dermatitis (AD) and was recently approved in Japan. In this study, we investigated the pharmacological and pharmacokinetic properties of difamilast to provide nonclinical data to help understand the clinical effects. Difamilast selectively inhibited recombinant human PDE4 activity in assays. The IC

Topics: Animals; Dermatitis, Allergic Contact; Dermatitis, Atopic; Humans; Leukocytes, Mononuclear; Mice; Phosphodiesterase 4 Inhibitors; Rats; Swine; Tumor Necrosis Factor-alpha